Intrepid Labs integrates AI, robotics, and advanced formulation science to accelerate drug development. Our proprietary VALIANT™ platform optimizes formulations for global pharma and CDMO partners. In parallel, we are advancing next-generation proprietary drug delivery technologies for use in oral and long-acting injectable formulations of small molecules and peptides. For more information, please visit https://intrepidlabs.tech/

For more information, please visit https://www.samyang.com/en/index

For more information, please visit https://www.phchd.com/global

Ozette is a biotechnology company pioneering vertically integrated and computationally-driven solutions for deep immune profiling. By combining advanced AI-driven analysis with high quality & high-dimensional single-cell data generation in our Laboratory, Ozette is transforming immunological insights into actionable knowledge, empowering biopharmaceutical companies to develop precision therapies for complex diseases.

For more information, please visit https://www.ozette.com/

ICON Biotech is a world leading healthcare intelligence and clinical research organisation, dedicated to the needs of small and mid-sized biopharma companies. With 8,000 dedicated staff, we help biotech organisations meet their critical milestones and deliver data and evidence-based results to investors, large pharma partners and regulatory authorities. For more information, please visit https://www.iconplc.com/sectors/biotech

Johnson & Johnson’s Innovative Health, Engagement, and Advocacy (IHE&A) serves as a central function for our global development, leading the expansion of capabilities to enhance trial operations and better serve patients. The IHE&A sub-team focuses on enabling global patient access to our drug development pipeline, partnering with key advocacy communities to amplify patient voices across the R&D industry, and future-proofing patient engagement strategy with impactful capabilities and solutions.

Miracle accelerates clinical trials with real-time, automated insights across enrollment, patient profiles, safety, labs, data management, forecasting, and more. By aggregating and harmonizing siloed data, Miracle helps biopharma companies reduce delays, make faster decisions, and centralize communication. Customers have cut months off trial timelines by eliminating manual processes and inefficiencies. For more information, please visit https://www.miracleml.com/

For more information, please visit https://www.nelipak.com/

Alpha Clinical is a boutique consulting firm specializing in clinical development, end-to-end pharmacovigilance services, regulatory affairs, and R&D consulting. We provide comprehensive solutions, including clinical operations, site management, medical affairs, and strategic due diligence, ensuring compliance with global standards while prioritizing patient safety. Our expertise drives excellence across the pharmaceutical and biotech industries. For more information, please visit https://alphaclinicaldevelopments.com/

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998. For more information, visit https://hcwco.com/

Capish develops unprecedented tools for visualization and exploration of data, offering customer-specific solutions tailored to meet the complex challenges of clinical research. For more information, please visit https://www.capish.com/

ImmuVia is a biotechnology company pioneering a new class of oncology therapeutics—Cancerlysins™—innovative bispecific antibodies designed to radically improve treatment outcomes while overcoming the limitations of all prior approaches. Our flagship candidate, Cancerlysin IMV-M™, is the first molecule to robustly induce apoptosis in targeted cells without relying on cytotoxic payloads or the internalization of antibody constructs—key limitations of ADCs. As a leader in bispecific antibody development, we are excited to connect with industry experts, researchers, and potential partners at the IO360° Summit 2025. For more information, visit https://immuviatx.com/